Page last updated: 2024-12-10
(3-iodobenzyl)trozamicol
Description
(3-iodobenzyl)trozamicol is a **radiolabeled derivative of trozamicol**, a drug used to treat **peripheral vascular disease** by improving blood flow. It's important for research because it allows scientists to **study the distribution, metabolism, and pharmacokinetics of trozamicol** in living organisms using **positron emission tomography (PET)**.
Here's a breakdown:
* **Trozamicol:** A drug used to improve blood flow in the legs and feet.
* **(3-iodobenzyl)trozamicol:** A modified version of trozamicol where an iodine-123 atom has been added to a specific position in the molecule.
* **Iodine-123:** A radioactive isotope that emits positrons, making it suitable for use in PET imaging.
* **PET imaging:** A technique that uses radioactive tracers to visualize the distribution and activity of certain molecules in the body.
**Why is this important for research?**
* **Understanding drug distribution:** By using (3-iodobenzyl)trozamicol in PET imaging, researchers can track the movement of the drug throughout the body. This can provide valuable insights into how the drug reaches its target tissues and how it is eliminated.
* **Investigating drug metabolism:** PET imaging with this tracer can reveal how the body processes the drug and how it is broken down. This information is crucial for optimizing drug dosage and minimizing side effects.
* **Assessing drug efficacy:** By visualizing the drug's action in the body, researchers can assess the effectiveness of trozamicol in treating peripheral vascular disease and potentially identify new applications for the drug.
In short, (3-iodobenzyl)trozamicol is a valuable tool for research because it provides a non-invasive way to study the distribution, metabolism, and efficacy of trozamicol in living organisms. This information can be used to improve drug development, optimize treatment strategies, and gain a deeper understanding of the drug's mechanism of action.
(3-iodobenzyl)trozamicol: a high-affinity vesamicol receptor ligand; RN refers to (trans-(-))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 3035815 |
| MeSH ID | M0217781 |
Synonyms (11)
| Synonym |
|---|
| meta-iodobenzyltrozamicol |
| (3s,4s)-1-[(3-iodophenyl)methyl]-3-(4-phenylpiperidin-1-yl)piperidin-4-ol |
| mibt-3 |
| 3-iodobenzyl-4-azavesamicol |
| 4-hydroxy-1-(3-iodobenzyl)-3-(4-phenylpiperidinyl)piperidine |
| 1'-((3-iodophenyl)methyl)-4-phenyl-(1,3'-bipiperidin)-4'-ol trans-(-)- |
| (m-iodobenzyl)trozamicol |
| (1,3'-bipiperidin)-4'-ol, 1'-((3-iodophenyl)methyl)-4-phenyl-, trans-(-)- |
| (3-iodobenzyl)trozamicol |
| 148519-95-3 |
| DTXSID30164003 |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.97
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 11.97 (24.57) | | Research Supply Index | 2.20 (2.92) | | Research Growth Index | 4.17 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |